ResearcherGeorgetown UniversityActive in the last 2 years

Ali Jaber Alqahtani

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6437-5843; OpenAlex author ID A5015192487. Sources: OpenAlex.

Their work

Papers: 3 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 7

Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 3

Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a multicentre retrospective study. Co-author DOI 10.1186/s12885-024-13386-0 ↗
Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic revi… Co-author DOI 10.1016/j.suronc.2023.102007 ↗
The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways. First author DOI 10.3390/cancers14112619 ↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Chao Yin · 2 shared papers, 2022–2023 · strength 0.48
- Paper The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways. DOI 10.3390/cancers14112619 ↗
- Paper Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic … DOI 10.1016/j.suronc.2023.102007 ↗
Marcus Smith Noel · 1 shared paper, 2022 · strength 0.26
- Paper The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways. DOI 10.3390/cancers14112619 ↗
Reetu Mukherji · 1 shared paper, 2023 · strength 0.22
- Paper Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic … DOI 10.1016/j.suronc.2023.102007 ↗
Benjamin Adam Weinberg · 1 shared paper, 2023 · strength 0.22
- Paper Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic … DOI 10.1016/j.suronc.2023.102007 ↗
Mohamed Aseafan · 1 shared paper, 2025 · strength 0.18
- Paper Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a m… DOI 10.1186/s12885-024-13386-0 ↗
Nedal Bukhari · 1 shared paper, 2025 · strength 0.18
- Paper Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a m… DOI 10.1186/s12885-024-13386-0 ↗
Shouki N. Bazarbashi · 1 shared paper, 2025 · strength 0.18
- Paper Real-world clinical outcome of unresectable locally advanced & de-novo metastatic pancreatic ductal adenocarcinoma: a m… DOI 10.1186/s12885-024-13386-0 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.